Overview

The Safety and Efficacy of Lurasidone In Subjects With Schizophrenia Switched From Olanzapine

Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
An open-label, single-arm and multi-center study for 16 weeks
Phase:
Phase 4
Details
Lead Sponsor:
Sumitomo Pharmaceutical (Suzhou) Co., Ltd.
Treatments:
Lurasidone Hydrochloride